HC Wainwright Lowers Earnings Estimates for Pharming Group

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) – HC Wainwright cut their FY2026 earnings per share estimates for shares of Pharming Group in a report issued on Tuesday, October 27th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of $0.25 for the year, down from their previous forecast of $0.45. HC Wainwright has a “Buy” rating and a $37.00 price objective on the stock. The consensus estimate for Pharming Group’s current full-year earnings is $0.32 per share.

Pharming Group (NASDAQ:PHAR) last issued its earnings results on Tuesday, October 27th. The company reported $0.30 earnings per share for the quarter, beating analysts’ consensus estimates of $0.21 by $0.09. Pharming Group had a return on equity of 3.40% and a net margin of 2.51%. The business had revenue of $117.60 million during the quarter, compared to analyst estimates of $117.60 million.

PHAR has been the subject of several other reports. Wall Street Zen upgraded Pharming Group to a “hold” rating in a report on Saturday, October 24th. Oppenheimer reaffirmed an “outperform” rating on shares of Pharming Group in a research note on Wednesday. Weiss Ratings upgraded shares of Pharming Group from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday. Zacks Research raised shares of Pharming Group from a “strong sell” rating to a “hold” rating in a research report on Friday, October 23rd. Finally, Canaccord Genuity Group set a $38.00 target price on shares of Pharming Group in a research report on Wednesday, September 23rd. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $38.67.

Pharming Group Price Performance

PHAR opened at $12.26 on Thursday. Pharming Group has a 12-month low of $9.11 and a 12-month high of $21.34. The company has a current ratio of 3.01, a quick ratio of 2.31 and a debt-to-equity ratio of 0.34. The business’s fifty day simple moving average is $10.70 and its 200-day simple moving average is $13.86. The company has a market capitalization of $867.74 million, a price-to-earnings ratio of 102.17 and a beta of -0.05.

Institutional Trading of Pharming Group

A hedge fund recently bought a new position in Pharming Group stock. MAC Alpha Capital Management LP bought a new stake in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 2,148,144 shares of the company’s stock, valued at approximately $29,838,000. Pharming Group comprises about 6.0% of MAC Alpha Capital Management LP’s investment portfolio, making the stock its 2nd largest holding. MAC Alpha Capital Management LP owned 3.03% of Pharming Group as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 0.03% of the company’s stock.

Key Stories Impacting Pharming Group

Here are the key news stories impacting Pharming Group this week:

• Positive Sentiment: Strong Q3 performance: Third-quarter revenue increased 21% year over year to $117.6 million, matching expectations, while operating profit rose 89% to $29.9 million. Earnings of $0.30 per share exceeded the $0.15 consensus estimate. Pharming Group third-quarter 2026 financial results
• Positive Sentiment: Both key products grew: Ruconest revenue rose 14% to $93.8 million as demand stabilized, while Joenja revenue jumped 58% to $23.8 million on strong U.S. and international demand. Joenja is also expanding through a U.S. pediatric label and launches in Germany and Japan. Joenja gains momentum and Ruconest returns to growth
• Positive Sentiment: Financial position strengthened: Pharming generated $32.4 million in quarterly operating cash flow, ending the period with $190.9 million in cash. Management tightened its 2026 revenue outlook to $380 million–$390 million from $375 million–$395 million, signaling greater confidence in the forecast.
• Positive Sentiment: Analyst outlook improved: HC Wainwright maintained a Buy rating and $37 price target, while raising its FY2027 EPS forecast to $0.59 from $0.56. The target implies substantial upside relative to recent trading levels. Pharming Q3 2026 earnings call transcript
• Neutral Sentiment: Upcoming catalyst: Pharming expects topline data in November from a Phase II trial of leniolisib in a broader common variable immunodeficiency (CVID) population. Positive data could support Joenja’s expansion, while disappointing results would create downside risk. Pharming Q3 revenue and CVID data
• Negative Sentiment: Near-term earnings remain uneven: HC Wainwright expects a $0.01-per-share loss in the fourth quarter, and PHAR’s valuation remains demanding at roughly 102 times earnings, increasing sensitivity to clinical or commercial setbacks.

About Pharming Group

Pharming Group N.V. is a biopharmaceutical company headquartered in Leiden, the Netherlands. The company develops and commercializes medicines for rare diseases and operates internationally, serving patients and healthcare providers in North America, Europe and other selected markets.

Pharming’s principal product is Ruconest, a recombinant C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause potentially serious swelling. The company also markets Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency.